INCY - Incyte Corporation

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

62.99

+0.64 (+1.03%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	62.35
Open	62.61
Bid	62.69 x 100
Ask	63.80 x 100
Day's Range	62.35 - 63.93
52 Week Range	61.30 - 140.11
Volume	3,689,835
Avg. Volume	2,434,927

Market Cap	13.341B
Beta	1.12
PE Ratio (TTM)	N/A
EPS (TTM)	-1.53
Earnings Date	May 1, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	82.31

Trade prices are not sourced from all markets

All

News

Press Releases

Business Wire17 minutes ago
Incyte to Present at Upcoming Investor Conference
Incyte Corporation announced today that it will present at the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 at 8:40 am PDT in Las Vegas.
Business Wire15 hours ago
Incyte Highlights Abstracts Accepted for Presentation at the 2018 ASCO Annual Meeting
Incyte Corporation announces that multiple abstracts from its research and development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology annual meeting in Chicago, Illinois from June 1-5, 2018.
Motley Fool22 hours ago
Lessons to Learn From April's Biotech Blowups
Three biotechs reported devastating clinical trial failures this month. Here are the important takeaways.
ACCESSWIREyesterday
Today's Research Reports on Trending Tickers: Allergan and Incyte Corporation
NEW YORK, NY / ACCESSWIRE / April 25, 2018 / The markets recent slide continued Tuesday as concerns of rising interest rates continued to plague investors. On Tuesday, the yield on the benchmark on the ...
TheStreet.com2 days ago
Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug
rheumatoid arthritis drug baricitinib, Eli Lilly chairman and CEO David Ricks on an earnings call Tuesday expressed confidence in the benefit-risk profile of both doses of the treatment. The advisory panel recommended that the FDA approve the 2-mg dose of baricitinib, but not the 4-mg dose for the proposed indication based on the adequacy of the safety and benefit-risk profiles. "While we are pleased that the FDA's arthritis advisory committee supported the efficacy of both 2 mg and 4 mg of baricitinib in RA and 2 mg overall, we are disappointed that the committee did not recommend approval of the 4-mg dose," Ricks said.
MarketWatch2 days ago
Eli Lilly, Incyte shares drop after mixed FDA drug recommendation
Eli Lilly & Co. shares dropped nearly 3% in premarket trade Tuesday after the company's rheumatoid arthritis therapy baricitinib was recommended for Food and Drug Administration approval at the 2-mg dose, but not the 4-mg dose. Incyte Corp. , a partner on the drug, had its shares drop nearly 5% premarket. The recommendation, made by the FDA's arthritis advisory committee late Monday, was based on concerns about the 4-mg dose's safety and risks relative to its benefits.
CNBC2 days ago
Eli Lilly's earnings beat expectations, and its improved outlook overcomes regulatory setback
Eli Lilly shares gain after the drugmaker beats first-quarter earnings expectations.
PR Newswire2 days ago
FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
INDIANAPOLIS, April 23, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the Advisory Committee unanimously supported the efficacy of the 4-mg dose of baricitinib, it did not recommend approval of the 4-mg dose of baricitinib for the proposed indication based on the adequacy of the safety and benefit-risk profiles.
Reuters3 days ago
FDA panel against higher dose of Lilly-Incyte arthritis drug
An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.
PR Newswire6 days ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY)
NEW YORK , April 20, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Incyte Corporation ("Incyte" ...
Motley Fool6 days ago
3 Biotech Stocks With Major Catalysts Incoming
Highly anticipated events expected in the weeks ahead could set these three biotechs up for long-term success.
PR Newswire7 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY
NEW YORK , April 19, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation ("Incyte" or the "Company") (NASDAQ: INCY). Such investors ...
Bloomberg7 days ago
Eli Lilly's Blockbuster Resurrection Story Has Holes
Its arthritis drug's new lease on FDA life apparently comes with conditions.
MarketWatch7 days ago
Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug
Gilead Sciences Inc. shares dropped 2.1% in moderate Thursday trade after a Food and Drug Administration briefing document raised safety questions about a similar Eli Lilly & Co. and Incyte Corp. drug. ...
MarketWatch7 days ago
Eli Lilly, Incyte shares fall after FDA cites issues with rheumatoid arthritis drug
Eli Lilly & Co. shares fell 1.8% premarket and Incyte Corp. shares dropped 4.5% premarket on Thursday after a Food and Drug Administration briefing document raised issues with their rheumatoid arthritis drug baricitinib. The drug will go up before a FDA arthritis advisory committee meeting on Monday. The FDA often follows an advisory committee's recommendation, though there are exceptions.
Reuters7 days ago
FDA staff cites safety issues for Lilly, Incyte's rheumatoid arthritis drug
The U.S. Food and Drug Administration staff on Thursday flagged concerns about potentially fatal blood clots from higher doses of Eli Lilly and Co and Incyte Corp's rheumatoid arthritis drug. An independent ...
Motley Fool10 days ago
What Incyte's Phase 3 Fail Means for Immuno-Oncology
Incyte’s phase 3 Epacadostat trial wasn’t so hot, and stocks all across biotech are feeling the burn.
Investor's Business Daily10 days ago
NewLink Shares Bite The Dust After Merck-Incyte Melanoma Failure
NewLink toppled Monday after it scrapped a late-stage study of its immuno-oncology drug in combination with drugs from Merck and Bristol.
Motley Fool10 days ago
What's Next for Incyte?
With a key pipeline drug nixed, Incyte has a few more question marks on the horizon than it did before.
MarketWatch10 days ago
NewLink shares fall on late-stage trial changes
NewLink Genetics Corp. shares fell as much as 15% in premarket trade Monday after the company said it won't proceed as planned with a late-stage trial of its indoximod for advanced melanoma. The company ...
Zacks10 days ago
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
Motley Fool13 days ago
What Happened With Incyte's IDO Inhibitor Flop
Investor confidence in epacadostat was through the roof, and the drug's phase 3 flop crushed the stock in a big way.
Zacks13 days ago
Pharma M&A Active This Week: 4 Potential Buyout Targets
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
Market Realist13 days ago
Incyte: S&P 500’s Top Gainer on April 12
The S&P 500’s top gainers on April 12 were: Incyte (INCY) gained 5.3%. Micron Technology (MU) gained 4.2%. Host Marriott Financial Trust (HST) gained 4.1%. Deere & Company (DE) gained 4.1%. Discovery (DISCK) gained 3.9%. Incyte
Business Wire13 days ago
Incyte to Report First Quarter Financial Results
Incyte Corporation announced today that it has scheduled its first quarter 2018 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 1, 2018.